Phase 3 N=6 Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia
Juvenile Primary Fibromyalgia Syndrome (JPFS) · Fibromyalgia
Primary: Average Pain Severity Score — 62 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=184 A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
Fibromyalgia
Primary: Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) Modified Short Form-adolescent Version 24 Hour Average Pain Severity Item — -1.62; -0.97 units on…
Phase 3 N=114 Coping Skills Training for Adolescents With Fibromyalgia
Fibromyalgia
Primary: Change in FDI (Functional Disability Inventory) Scores at End of Study — 21.4; 19.2; 13.4; 17.0 units on a 0-60 scale — p=0.007
N/A N=40 Fibromyalgia Integrative Training for Teens
Juvenile Fibromyalgia
Primary: Average Pain Intensity — 6.26; 6.41; 4.69; 6.38 units on a scale — p=.011
N/A N=317 Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale
Phase 4 N=107 Adolescent Fibromyalgia Study
Fibromyalgia
Primary: Change From Baseline to Week 15 in Mean Pain Diary Score — -1.60; -0.94 Units on a scale — p=0.121
Phase 4 N=63 Pregabalin In Adolescent Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline in Pain Numeric Rating Scale by Week — 6.7; -2.1; -1.8; -2.1 Number
Phase 3 N=289 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Change in Pain Intensity — 3.56; 3.26; 3.07; 2.90 Units on a scale — p=<.001
N/A N=16 Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention
Juvenile Idiopathic Arthritis
Primary: Feasibility as Assessed by Adherence — 12 Participants
N/A N=23 Jointstrong Intervention for Juvenile Arthritis
Juvenile Arthritis
Primary: Pain — 4.3; 5.7 units on a scale
Phase 1 N=26 Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour
Phase 2 N=71 Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
Phase 4 N=12 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants
N/A N=100 Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Sleep Disturbance — 62.1; 62.4; 57.7; 58.3 T-score
Phase 3 N=190 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002
Phase 3 N=139 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
Juvenile Dermatomyositis
Primary: Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by >…
Phase 4 N=85 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
Juvenile Chronic Polyarthritis · Juvenile Idiopathic Arthritis · Juvenile Rheumatoid Arthritis
Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants
Phase 3 N=1,270 Treatment of Pain Associated With Fibromyalgia
Pain Associated With Fibromyalgia
Primary: Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo — -1.86; -2.47; -2.24; -2.09 units on a…
Phase 3 N=1,293 Treatment of Pain Associated With Fibromyalgia
Pain Associated With Fibromyalgia
Primary: Change From Baseline in Weekly Average Daily Pain Score (ADPS) at Week 13 in Participants Receiving DS-5565, Pregabalin, Placebo — -1.66; -1.90; -1.97; -1.93 units on a…
Phase 3 N=1,301 Treatment of Pain Associated With Fibromyalgia
Pain Associated With Fibromyalgia
Primary: Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo — -1.90; -2.64; -2.04; -2.30 units on a…
N/A N=95 Positive Affect as a Source of Resilience for Adults in Chronic Pain
Geriatric · Chronic Pain
Primary: Recruitment as Measured by Rates of Enrollment (Aim 1) — 120; 95; 22; 2 Participants
Phase 3 N=32 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants
N/A N=28 Feeling and Body Investigators for Pediatric Abdominal Pain
Functional Abdominal Pain
Primary: Number of Participants Who Complete Treatment — 22 Participants
Phase 2 N=7 Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
Fibromyalgia
Primary: Heart Rate Beats Per Minute (BPM) - First Dose (15 mg) — 76; 67; 67; 68 Heart beats per minute
Phase 3 N=193 A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Fibromyalgia
Primary: Mean NRS Pain Score at End of Period. — 4.84; 5.45 Units on a scale — p=0.0001
Phase 3 N=193 Pediatric Arthritis Study of Certolizumab Pegol
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
Phase 3 N=25 Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 — 23 Participants
Phase 2 N=36 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Phase 3 N=133 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Arthritis, Juvenile Idiopathic
Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031
N/A N=43 Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)
Fibromyalgia
Primary: Pain at Rest Difference Score Pre-intervention and Post Intervention — 0.38; -0.74; -0.47 units on a scale